Aurora Burlington Charges $265 for Human Papillomavirus High Risk Test Without Papanicolaou Test

The Human Papillomavirus (HPV) High Risk Test (without Papanicolaou/Pap test) at Aurora Burlington is priced at $265. This diagnostic procedure screens specifically for high-risk HPV strains that are strongly linked to the development of cervical cancer. The fee typically covers the laboratory analysis of a cervical or vaginal sample for the presence of these high-risk HPV types, but may not include additional services such as specimen collection, provider consultation, or follow-up visits. Patients are advised to request a fully itemized estimate in advance, clarify whether sample collection and interpretation are included, and check with their insurance provider about coverage for HPV testing.

Cost Breakdown

• HPV High Risk Lab Test: $265 (lab processing and analysis of the sample)
• Not Included: Office visit fees, sample collection charges, provider consultation, follow-up care, or additional lab tests (such as Pap smear) may be billed separately.

Associated Costs to Consider

• Specimen collection fee (if performed during a clinic visit)
• Office visit or consultation fee
• Follow-up testing or procedures if results are positive
• Pathology review (if abnormal cells are found and further analysis is needed)

Insurance & Payment Advice

• Check with your insurance provider about coverage for standalone HPV testing; some plans may only cover it when performed with a Pap test.
• If you are uninsured or have a high-deductible plan, ask about self-pay discounts or payment plans.
• Request all fees in writing and confirm what is included to avoid surprise bills.

Frequently Asked Questions

• What does the $265 fee for the HPV High Risk Test cover?
  The $265 fee generally includes laboratory analysis of your sample for high-risk HPV strains but may not cover collection, office visit, or follow-up charges. Always confirm the full scope with the provider.
• Is the Pap smear included in this test?
  No, the Pap smear (Papanicolaou test) is not included. This fee is only for the HPV High Risk Test performed without a Pap test.
• Will insurance cover this test?
  Coverage varies by plan. Some insurances may only cover HPV testing when combined with a Pap smear or for certain age groups. Contact your insurer for details.
• Are there additional costs besides the $265?
  Yes, you may incur charges for the office visit, sample collection, or follow-up care, depending on your situation and provider billing policies.
• Who should get the HPV High Risk Test without a Pap?
  This test is generally recommended for women over age 30, or as advised by your healthcare provider, to screen for high-risk HPV strains that may increase cervical cancer risk.
• How is the HPV High Risk Test performed?
  A sample is typically collected from the cervix or vagina during a pelvic exam and sent to the lab for analysis.
• What happens if my test is positive?
  Your provider may recommend additional testing, such as a Pap smear or colposcopy, to further evaluate cervical health.
• Can I request a price estimate before the test?
  Yes, you should request an itemized estimate that details all potential charges, including lab, collection, and office visit fees.
• Is financial assistance available?
  Some clinics offer payment plans or discounts for uninsured or self-pay patients. Ask the billing office about your options.
• Will this test require any recovery time?
  No recovery time is typically needed. You can resume normal activities immediately after the sample is collected.
• Can men get the HPV High Risk Test?
  The test is primarily used for cervical cancer screening in women; routine high-risk HPV testing is not typically performed for men.

The Aurora Medical Center Burlington offers a Human Papillomavirus (HPV) High Risk Test without a Papanicolaou (Pap) test for a fee of $265. This medical service is designed to detect the presence of high-risk HPV strains that are associated with an increased risk of cervical cancer. The test is crucial for identifying individuals who may require further monitoring or intervention to prevent the progression of potential cervical abnormalities. By focusing on high-risk HPV types, the test provides valuable information for healthcare providers to make informed decisions about patient care and management.

What is the HPV High Risk Test without Pap? – The HPV High Risk Test without Pap is a diagnostic procedure that screens for high-risk strains of the Human Papillomavirus, which are linked to cervical cancer, without performing a Pap smear.

Why is the HPV High Risk Test important? – This test is important because it helps identify individuals at risk for cervical cancer, allowing for early intervention and management to prevent the development of cancer.

Who should consider getting the HPV High Risk Test? – Individuals, particularly women, who are sexually active and have not had a recent Pap test or those who have been advised by their healthcare provider to monitor HPV status should consider this test.

How is the HPV High Risk Test performed? – The test is typically performed by collecting a sample of cells from the cervix, which is then analyzed in a laboratory to detect the presence of high-risk HPV strains.

What does a positive result on the HPV High Risk Test mean? – A positive result indicates the presence of high-risk HPV strains, suggesting a need for further evaluation and possibly more frequent monitoring to prevent cervical cancer.

Is the HPV High Risk Test covered by insurance? – Coverage for the HPV High Risk Test varies by insurance provider and plan, so it is recommended to check with your insurance company to determine if the test is covered.

How often should one get the HPV High Risk Test? – The frequency of testing depends on individual risk factors and healthcare provider recommendations, but generally, it is suggested every three to five years for women aged 30 and older.

What should one do if they test positive for high-risk HPV? – If you test positive, it is important to follow up with your healthcare provider for further evaluation and to discuss potential next steps, which may include additional testing or monitoring.